Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study .
Myovant Sciences, Inc.January 26, 2021 GMT
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
82.8% average reduction from baseline
on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain)
over one year
Bone mineral density loss was minimal at Week 24 and remained stable through one year
Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021
(2)
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY,
January
, 2021 (GLOBE NEWSWIRE) - Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment (AMC) financial mechanism that aims
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat .
BioNTech SEJanuary 22, 2021 GMT
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY, January 22, 2021 (GLOBE NEWSWIRE) Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
BioNTech SE
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY,
January
, 2021 (GLOBE NEWSWIRE) Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
Message :
Required fields
https://www.globenewswire.com/Tracker?data=dLQu2aAz4um8AyDqR277DayDU54BtEparkmn QT0TWSvYLPLlEJErUilog7MTrBRvj7cGdJGn-lfP9PHPzE2zqFVD 2xGJd1zoxOh41As0g=
LinkedIn,
https://www.globenewswire.com/Tracker?data=S3vX2UO4EkSqbvO7nrkYGsZofOzZfb-GfvSiHGP-4nke5a9udcRa1gJnumQLKtubt8bFu28EZNyLkU3t-3ja7A==
YouTube and like us on Facebook at
https://www.globenewswire.com/Tracker?data=VsJbfzzbMEISTOVaElMUCfP5HautqIC3RTVi381Q5Z2gE Jb91VksIf002oDaeMUJLLSO96cl39YFMZrnejJKa3tc8WlqpfwpkQaDn7sDXU=
Facebook.com/Pfizer. Pfizer Disclosure Notice The information contained in this release is as of January 20, 2021.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future